Key Takeaways The FDA has accepted Opus Genetics' IND application for OPGx-BEST1, targeting BEST1-related inherited retinal disease. Best disease results from BEST1 gene mutations, causing macular ...

Vabysmo is now publicly funded in Quebec for macular edema secondary to RVO, including a pre-filled syringe format. The drug is a bispecific IgG1 antibody inhibiting Ang-2 and VEGF-A, approved for ...

Key Takeaways Syphilis can present with non-specific symptoms, complicating diagnosis, especially when co-infections like tuberculosis are suspected. Ocular syphilis, a form of neurosyphilis, often ...

4D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for potential market approval.

Eyestem Research secures $10 million funding to advance innovative retinal therapies, aiming for global expansion and promising trial results.

A study that investigated retinal neurovascular signatures in patients with Parkinson’s Disease (PD) found that some retinal parameters differed significantly compared with healthy controls, 1 ...

Ella Leung, MD, a vitreoretinal surgeon at Georgia Retina, presented a study on the economic impact of anti-VEGF prior authorization requests at the 2025 annual meeting of the American Society of ...

David Liao, MD, PhD, from Retina Vitreous Associates Medical Group in Los Angeles presented long-term follow-up data for MCO-010, a treatment candidate for patients with retinitis pigmentosa (RP).

In this 3-part article, ophthalmologists explore how robotic and AI technologies are refining laser-assisted cataract surgery. • Vance Thompson, MD, details how robotic integration in the operating ...

Roger A. Goldberg, MD, MBA, from Bay Area Retina Associates presented 48-month data on pegcetacoplan for geographic atrophy (GA) treatment at the ASRS 2025 conference in Long Beach, California. The ...

David Eichenbaum, MD, FASRS, a partner and director of research at Retina Vitreous Associates of Florida and collaborative volunteer Associate Professor at the Morsani College of Medicine, University ...

PolyActiva has enrolled the first patient in its phase 2b clinical trial evaluating PA5108, an investigational, new chemical entity (NCE), intracameral ocular microimplant, for reducing IOP in ...